Search results
RTS,S/AS01 (commercial name Mosquirix) is the only malaria vaccine approved and in current use. The vaccine's use requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30%. History
About. Malaria vaccines. Vaccine-Preventable Diseases. WHO updated its recommendation for malaria vaccines in October 2023. This applies to both RTS,S/AS01 and R21/Matrix-M vaccines.
Jan 19, 2024 · What is the RTS,S malaria vaccine? The RTS,S malaria vaccine, also known as Mosquirix, was developed by GlaxoSmithKline (GSK) in partnership with the PATH Malaria Vaccine Initiative and is designed to target the Plasmodium falciparum parasite that causes malaria, which is spread by anopheles mosquitoes. How does it work?
Oct 6, 2021 · The vaccine, called Mosquirix, is not just a first for malaria — it is the first developed for any parasitic disease. Parasites are much more complex than viruses or bacteria, and the quest...
Mar 4, 2022 · WHO today published an updated position paper on the RTS,S/AS01 (RTS,S) malaria vaccine that includes the October 2021 recommendation calling for the wider use of the vaccine among children living in areas of moderate-to-high P. falciparum malaria transmission.
Oct 7, 2021 · Years of clinical trials have shown that this vaccine—known as RTS,S/AS01, or Mosquirix—is safe and helps protect against the disease, especially in concert with other...
Oct 7, 2021 · JASON BEAUBIEN, BYLINE: The vaccine known as RTS,S was first developed in a GlaxoSmithKline laboratory in 1987, but it's taken decades to get it to the point where it can be deployed broadly...
